Skip to main content

Clinical Trials Using Paclitaxel

Review the clinical trials studying paclitaxel on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 176-195 of 195

Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
Status: Active
Location: See ClinicalTrials.gov
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Status: Active
Location: See ClinicalTrials.gov
Study of Novel Treatment Combinations in Patients With Lung Cancer
Status: Active
Location: See ClinicalTrials.gov
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Status: Active
Location: Wayne State University/Karmanos Cancer Institute, Detroit, Michigan
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
Status: Active
Location: See ClinicalTrials.gov
Paclitaxel or Liposomal Doxorubicin for HIV-positive Persons with Kaposi Sarcoma
Status: Approved
Location: Location information is not yet available.
Risk-Adapted, Proteomic-Guided (PROphet CB, and CARG-TT) Systemic Therapy for the Treatment of Previously Untreated Unresectable or Metastatic Non-small Cell Lung Cancer
Status: Approved
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
A Cancer Vaccine (STEMVAC) in Combination with Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
Status: Approved
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Nivolumab and Ipilimumab in Treating Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery
Status: Temporarily Closed to Accrual
Location: 424 locations
Study of Chemotherapy plus Ipatasertib for People with Solid Tumors with PTEN/AKT Mutations, A ComboMATCH Treatment Trial
Status: Temporarily Closed to Accrual
Location: 177 locations
Vactosertib for the Treatment of Patients who are Undergoing Standard of Care Chemoradiation for Locally Advanced Esophageal Cancer
Status: Temporarily Closed to Accrual
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Atezolizumab with Chemotherapy in Treating Patients with Anaplastic or Poorly Differentiated Thyroid Cancer
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Cryocompression with or without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients with Gynecological Cancers
Status: Active
Location: 4 locations
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment with Paclitaxel
Status: Temporarily Closed to Accrual
Location: 30 locations
Targeted Therapy Directed by Genetic Testing in Treating Patients with Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Status: Active
Location: 450 locations
Desloratadine for the Prevention of Taxane-Induced Peripheral Neuropathy in Patients with Stage I-III Breast Cancer, DETOXp Trial
Status: Approved
Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York
Implantable Microdevice for the Delivery of Drugs and their Effect on Tumors in Patients with Sarcoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Evaluation of De-Escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California